IBT-B Infant Bacterial Therapeutics AB (publ)

6.843USD69.40 SEK · STO-2.25%Mkt Cap: 92.19M USDP/E: —

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug c…

Institutional holders1 on file

Key Statistics

Company
Market Cap92.19M USD
Enterprise Value76.97M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.43M USD
Revenue/Share—
Last Price6.843 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0008015259
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B8.88
EPS (TTM)-0.68 USD
EPS (Forward)—
52W Range
4.26563% of range8.372
52W High8.372 USD
52W Low4.265 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-61.87%
ROA-40.29%
ROIC—
ROCE-65.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.13M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-4.16%
Net Debt-10.71M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio1.67
Quick Ratio1.66
Book Value/Sh0.77 USD
Cash/Share0.79 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.02M
Float11.23M
Insiders14.52%
Institutions36.71%
Technical
SMA 507.045 (-2.9%)
SMA 2006.075 (+12.6%)
Beta0.28
S&P 52W Chg8.68%
Avg Vol (30d)10.09K
Avg Vol (10d)9.19K
Technical Indicators
RSI (14)46.9
MACD-0.9579
MACD Signal-0.5479
MACD Hist.-0.4100
BB Upper7.723 USD
BB Middle7.008 USD
BB Lower6.292 USD
BB Width20.43%
ATR (14)0.5302 USD
Vol Ratio (20d)0.33x

About Infant Bacterial Therapeutics (STO: IBT-B)

›

Infant Bacterial Therapeutics (STO: IBT-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.

The shares were at 69.40 SEK on 20 November 2026, up 18.4% over 52 weeks. Its 52-week range is 43.25 SEK to 84.90 SEK: the price is 18.3% below the high and 60.5% above the low.

Its market capitalisation is 934.92M SEK.

Infant Bacterial Therapeutics reports return on equity of -61.9% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 108.60M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.